INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN

Pomerantz Law Firm has filed class action lawsuits against Regeneron Pharmaceuticals, Capricor Therapeutics, and GPGI, Inc. for alleged securities fraud. The primary focus is on Regeneron, where a Phase III clinical trial for Fianlimab-Libtayo failed to meet its primary endpoint, causing the stock to decline significantly on two separate occasions in April and May 2026. Investors with losses are urged to contact the firm by September 14, 2026, to potentially become lead plaintiffs.